Ann: IMUGENE LICENSES CAR T DIRECTED OV THERAPY FOR SOLID TUMOURS, page-205

Some further important comments / information provided by Saul “Cancer Asskicker” Priceman later on during the webinar video.

I refer to this slide with comments below:

Video between 8:39 to 9:30 minutes

· Highlighted on the right is perhaps the most exciting dataset that we have achieved to date

· That in animals that have been cured from the combination (CF33 CD19 plus CD19 CAR T cells) then when we re-challenge them or inject tumour cells back into those animals, thereare prevented from growing.

· Suggesting thatthere is this long lasting, what we call memoryimmunity response that prevents grow of tumour cells following the combination.

· Supporting that this may work in recurrences in patients where this combination in patients more provide protective immunity in these animals and patients. So that is a very exciting response we see with the combination.

---------------------------------------------------------

Irefer to this slide with comments below:

Video between 8:39 to 19:40 minutes

· The second therapeutic response we see is this amplified intratumoural spread of the virus.

· When we inject the virus into the tumour they are spread by the virus alone because that is what onCARlytic viruses do by themselves.

· They infect tumour cells, they kill tumour cells and then they spread to neigbouring tumour cells, amplifying the therapeutic response, which is profound by CF33 alone.

· And we showed that it was even greater amplified when we combined with CD19 CAR T cells.

· You can see that in green sort of spread across the entire tumour.

· And we think this is one of the mechanisms by which this combination will be far greater than either therapeutic alone, providing a synergistic response with this combination.